In contrast, in a double-blind, randomized phase III trial (NCT03337724), the inclusion of ipatasertib to paclitaxel did not improvement of efficacy in terms of progression-free survival among HR + and HER2 − progressive breast cancer patients [109]. This evidence concerns the gene ERBB2 and breast cancer.